Key points from article :
Cambrian Bio has launched Amplifier Therapeutics, a new company focused on developing ATX-304, a pan-AMPK activator targeting aging-related diseases.
The company acquired Betagenon AB, a Swedish firm known for discovering AMPK activators, to continue its research under the Amplifier team. AMPK is an energy sensor that helps cells produce energy, but its activation decreases with age, contributing to metabolic and cardiovascular diseases.
ATX-304 has shown a good safety profile in early clinical trials and could potentially prevent major chronic conditions. James Hall, former CEO of Betagenon, will lead Amplifier Therapeutics alongside Cambrian’s clinical development expert Ruth Thieroff-Ekerdt. A Phase 1b study to test ATX-304’s mechanism will begin later this year.
